SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2025
Valid surrogate end-points in nonsmall cell lung cancer peri-operative systemic therapy trials: a systematic review.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrence-, progression-, disease- and event-free survival are often selected as the primary end-points for trials assessing peri-operative systemic therapy for nonsmall cell lung cancer (NSCLC). As overall survival (OS) has increased, these surrogates, which we hereafter collectively term "recurrence-/progression-free survivals (RPFS)", have become more attractive end-points.
methodsThis systematic review, without meta-analysis, was conducted in accordance with the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (UMIN000052558). Electronic databases were searched on 11 October 2023. English-language articles presenting a randomised controlled trial assessing neoadjuvant and/or adjuvant systemic therapy for NSCLC were included. The main outcome was the weighted Spearman's rank correlation coefficient (r) between the hazard ratios (HRs) of OS (HRos) and RPFS (HRrpfs). The weight assigned to each study was determined using the inverse variance of the log HRos. Pathological subtype and driver mutations were not questioned.
resultsWe identified 31 trials with a total of 15 776 patients. The weighted correlation coefficient was 0.86 based on the raw data from the 31 trials. After reciprocal duplication, the weighted correlation coefficient was 0.91 (p<0.001 for unweighted r). Subgroup analyses showed the correlation was 0.98 for trials with immune checkpoint inhibitors but was 0.54 for molecular targeted therapy
conclusionsWe hope that our data will justify the use of the HRs of recurrence-, progression-, disease- and event-free survival as primary end-points in peri-operative immune checkpoint inhibitor regimens for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.